Efficacy and Safety of Monotherapy with Enavogliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results of a 12-week, multi-center, randomized, double-blind, placebo-controlled, phase 2 trial.
Ye Seul YangKyung Wan MinSeok-O ParkKyung-Soo KimJae Myung YuEun Gyoung HongSung Rae ChoKyu Chang WonYong Hyun KimSeungjoon OhSung Hee ChoiGwanpyo KohWan HuhSu Young KimKyong Soo ParkPublished in: Diabetes, obesity & metabolism (2023)
Once-daily enavogliflozin monotherapy for 12 weeks is an effective, safe, and well-tolerated treatment for Korean patients with T2DM. This article is protected by copyright. All rights reserved.
Keyphrases
- placebo controlled
- double blind
- phase iii
- clinical trial
- phase ii
- open label
- combination therapy
- end stage renal disease
- phase ii study
- newly diagnosed
- ejection fraction
- study protocol
- chronic kidney disease
- peritoneal dialysis
- type diabetes
- prognostic factors
- skeletal muscle
- radiation therapy
- physical activity
- adipose tissue
- replacement therapy